G1/23: Marketed Products Are Prior Art

The Enlarged Board of Appeal issued its decision in G1/23 on July 2, 2025, addressing whether products put on the market before a patent filing date form part of the prior art when their composition or internal structure cannot be reproduced by the skilled person.

G1/23: Marketed Products Are Prior Art

The Three Questions Referred

The referral arose from divergent case law on whether a product's non-reproducibility should exclude it from the state of the art. To resolve this inconsistency, the following questions were referred:

Question 1: Is a product put on the market before the date of filing of a European patent application to be excluded from the state of the art within the meaning of Article 54(2) EPC for the sole reason that its composition or internal structure could not be analysed and reproduced without undue burden by the skilled person before that date?

Question 2: If the answer to question 1 is no, is technical information about said product which was made available to the public before the filing date (e.g. by publication of technical brochure, non-patent or patent literature) state of the art within the meaning of Article 54(2) EPC, irrespective of whether the composition or internal structure of the product could be analysed and reproduced without undue burden by the skilled person before that date?

Question 3: If the answer to question 1 is yes or the answer to question 2 is no, which criteria are to be applied in order to determine whether or not the composition or internal structure of the product could be analysed and reproduced without undue burden within the meaning of opinion G 1/92? In particular, is it required that the composition and internal structure of the product be fully analysable and identically reproducible?

The Three Answers

Answer to Question 1: No. A product put on the market before the date of filing of a European patent application cannot be excluded from the state of the art within the meaning of Article 54(2) EPC for the sole reason that its composition or internal structure could not be analysed and reproduced by the skilled person before that date.

Answer to Question 2: Yes. Technical information about such a product which was made available to the public before the filing date forms part of the state of the art within the meaning of Article 54(2) EPC, irrespective of whether the skilled person could analyse and reproduce the product and its composition or internal structure before that date.

Answer to Question 3: In view of the answers to Questions 1 and 2, an answer is not required.

The Board examined what would happen if non-reproducible products were excluded from the prior art. They found this would lead to an absurd result: if products that cannot be reproduced were not prior art, then skilled persons could not rely on any starting materials, since all materials ultimately come from sources that cannot be reproduced from scratch. This chain of reasoning would empty the state of the art entirely.

What This Means

The Enlarged Board has effectively established what amounts to an on-sale bar at the EPO. Products put on the market are prior art, regardless of whether their composition is secret or whether they can be reverse-engineered. This means that any product sold or made publicly available before the priority date is prior art, along with all its analysable properties and any technical documentation about the product. 

G1/23 clarifies that public availability determines prior art status, not reproducibility. The decision removes the legal fiction that commercially available products do not form part of the state of the art, and aligns EPO practice with commercial reality by confirming that products available to skilled persons cannot be excluded from patentability assessments solely because their composition or manufacturing method cannot be reproduced.

AI for patents.

Be 50%+ more productive. Join thousands of legal professionals around the world using Solve’s Patent Copilot™ for drafting, prosecution, invention harvesting, and more.

Related articles

How to Draft Patent Figures with Solve Intelligence

Solve’s Figure Builder is the integrated environment within the Solve platform where you can generate, edit, label and refine figures. It brings figures into the drafting process, alongside claim and specification drafting so consistency, and compliance with 37 CFR §1.84, is maintained across your application from the very first sketch to the version you file.

Key Takeaways:

  • Create, edit and finalize figures for your patent filings, both manually and with AI assistance.
  • Bring figure management into the heart of the drafting process to ensure you have the figures you need, when you need them.
  • Propagate changes in terminology and reference numerals across your whole application with ease.
  • Convert disclosure documents or claims into labelled line drawings in a single session, and then use them as the basis for your detailed description.

Bree Vculek Joins Solve

We're delighted to welcome Bree Vculek to Solve Intelligence as our newest Legal and Product Engineer.

Solve Intelligence and HGF Partner to Deliver Custom AI Patent Drafting Workflows

Solve Intelligence is pleased to announce a strategic partnership with HGF, one of Europe’s leading intellectual property firms. The collaboration is focused on a clear objective: customising AI-driven drafting workflows to meet the specific needs of HGF and some of its clients.

Rather than adopting a one-size-fits-all approach, HGF is working closely with Solve Intelligence to shape how the drafting platform behaves across different technologies, client preferences, and drafting styles. The built-in, customisable features available in Solve’s platform are what makes this possible.

"We evaluated the field carefully before committing. Solve Intelligence delivered the drafting quality our attorneys demand and integrated seamlessly into how they already work. We are investing in the foundation for HGF's future practice."

Richard Hodkinson, Chief Technology Officer at HGF

What FICPI's ABC Meeting 2026 Revealed About AI-Ready Patent Practice

Solve Intelligence participated as a sponsor of FICPI’s ABC Meeting 2026 in Nashville, with CEO and Co-founder Chris Parsonson, demonstrating the practical application of a purpose-built patent AI platform. Patent attorneys and litigators convened for a key session addressing a central question: what is required for AI to be ready for patent practice? 

Key Takeaways:

  • Solve Intelligence supports the full patent lifecycle across 700+ IP firms, from invention disclosure through litigation.
  • One firm that adopted Solve Intelligence mid-fiscal year exceeded its billing targets by $1 million by reallocating AI-saved time to higher-value work.
  • In-house teams now require outside counsel to use AI tools, making AI fluency a firm selection criterion rather than a differentiator.
  • Attorneys report that ROI is not simply about increasing speed, but about reallocating the time saved to higher-value strategies, cross-sell analysis, and client insights.